Please login to the form below

Not currently logged in
Email:
Password:

Eisai expands into Russia with Halaven launch

Breast cancer drug will be followed by epilepsy portfolio

Eisai cancer drug Halaven eribulin

Eisai has expanded its presence in the emerging markets by setting up a new sales and marketing operation in Russia.

Based in Moscow, the operation's first task will be to launch the Japan-based company's breast cancer treatment Halaven (eribulin) in the country – an event scheduled to happen within the next three months.

This will be followed by the entry into the Russian market of Eisai's approved epilepsy portfolio, including Zonegran (zonisamide) and Exalief (eslicarbazepine acetate).

On top of these planned launches, Eisai said it will also seek regulatory approval in the country for additional epilepsy drugs Fycompa (perampanel) and Inovelon (rufinamide).

As a member of the emerging BRIC (Brazil, Russia, India, China) countries, Russia has become a progressively more important healthcare market for pharma companies, with healthcare reforms increasing opportunities for the industry.

The market is expected to achieve annual growth rates of at least 15 per cent up to 2020 when it is estimated to reach a value of $60bn.

Gary Hendler, president and CEO of Eisai Russia and EMA, commented that entry into the Russian market was part of the company's wider strategy to gain a stronger foothold in the EMEA region.

“We currently have a number of products in the final stages of approval and hope to launch four to five products within a year of market entry,” he said.

“This will allow Russian patients' to have access to innovative treatments not previously available to them and further supports Eisai's human health care mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide."

The expansion comes two months after Eisai made its first moves into the market in South Africa, submitting its breast cancer drug Halaven (eribulin) and epilepsy treatment Fycompa (perampanel) to the Medicines Control Council.

The company said it is seeking to expand its global present by 2015 to reach more than 500 million patients.

28th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics